Antiretroviral Therapy

Browse more sub-categories

Resources: 58

HIV Medication Pocket Guide

Colorado AETC of the Mountain West AETC has updated their tri-fold reference guide of current HIV medications. Included are infrequently used medications and formulations.

To order copies call Colorado...

Publication Date
01/15/2019

AIDSinfo Illustrated Glossary

This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely. The glossary and images are also availabl...

Publication Date
02/20/2019
Review Date
02/20/2019

HIV Medication Chart Pad

Colorado AETC of the Mountain West AETC has updated its HIV medication chart for providers and patients. This resource features all currently approved antiretroviral drugs and is available as a pad wi...

Publication Date
06/01/2019
Review Date
10/22/2019

COVID-19 Update for People with HIV

Three sets of training slides covering what providers treating people with HIV should know about COVID-19. Overall learning objectives include identifying risk factors for and strategies to reduce sev...

Publication Date
04/09/2020

AETC National HIV Curriculum

The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 lessons and corresponding question bank topics offer...

Publication Date
09/14/2020
Review Date
09/08/2021

Injectable HIV Treatment

Training slides review the latest information on HIV injectable therapies in clinical trials, the patients who might be good candidates for this treatment, and potential challenges for providers.

Doc...

Publication Date
02/22/2021

CROI 2021 Report Back

Presentation slides include information and updates from CROI 2021 regarding:

  • IMPACT 2010
  • ATLAS-2M
  • Lenacapavir: Capella Study

Documents with preview

Publication Date
04/19/2021

CROI Update 2021

(Recorded on April 12, 2021)

Speaker:

Paul Edward Sax, MD

Brief Overview:

Dr. Sax provides a summary of important presentations from the 2021 Conference on Retroviruses and Opportunistic Infections. This...

Publication Date
04/21/2021

Antiretroviral Therapy: Keys to Success

Training slides cover initial antiretroviral therapy (ART) options based on the most recent HHS Adult/Adolescent Guidelines. Includes selecting the initial ART regimen considering viral load, CD4 coun...

Publication Date
04/29/2021

HIV Resource Library

New England AETC's HIV Resource Library is a compilation of curated resources and education packets on HIV, viral hepatitis, and related public health topics.

Each Library topic page is an organized li...

Publication Date
05/27/2021

Prevention IS Care

To help HIV care providers engage patients in care and transmission prevention, the Centers for Disease Control and Prevention (CDC) developed a new and comprehensive Prevention IS Care resource kit f...

Publication Date
06/30/2021

ART Drug Interactions

Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.

Documents with preview

Publication Date
09/22/2021

HIV and Injectable Drugs

Learning Objectives:

  • Summarize the evidence for long-acting injectable HIV treatment and prevention
  • Analyze the advantages and disadvantages of long-acting injectable antiretrovirals
  • Describe the impleme...
Publication Date
11/12/2021

CROI 2022 Update: HIV Prevention

Description:

Training slides provide a summary of HIV prevention updates presented at CROI 2022, including new data on CAB-LA PrEP and other prevention modalities like islatravir, and dapivirine vagina...

Publication Date
03/09/2022

Emerging HIV Treatment Options

Training slides provide an overview of the role of cabotegravir/rilpivirine injectables and other novel formulations in development for HIV treatment and prevention, and review shifting treatment para...

Publication Date
04/28/2022

CROI 2022 Update

Training slides provide an update on the epidemiology of HIV in the U.S., antiretrovirals, PrEP, the HIV “cure” case, COVID-19 prevention & treatment, and more from CROI 2022.

Preview and Downlo...

Publication Date
04/28/2022

IAS Update 2021 Webinar

(Recorded 8/11/21)

This recording includes updates from the virtual IAS 2021 Conference.

Speakers:

Kenneth Mayer, MD

Rebecca Zash, MD

Rajesh Gandhi, MD...

Publication Date
08/03/2022

Resources: 18

HIV & Aging

Objectives

  • Identify issues associated with treating older individuals with HIV infection
  • Discuss epidemiology and risk factors of co-morbidities in HIV-positive patients
  • Recommend management strategies f...
Publication Date
12/07/2016

Articles: 28

Cobicistat and Stribild Use in Patients with Renal Insufficiency

Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center

An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...

Ian
McNicholl

HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052

The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples engage...

Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study

The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing darunavir 800 mg/cobi...

Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain inter...